Palexia film coated tablets
Last Updated on eMC 15-Oct-2014 View document | Grunenthal Ltd Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 15-Oct-2014 and displayed until Current
Reasons for adding or updating:
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Date of revision of text on the SPC: 31-Jul-2014
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 4.2:'Elderly patients' replaced by 'Older people'
Section 4.8
Added 'and from post-marketing environment' to 'The table below lists adverse drug reactions that were identified from clinical trials performed with PALEXIA and from post-marketing environment'
Added - Rare adverse reaction of angioedema, anaphylaxis and anaphylactic shock
Added wording on reporting of suspected adverse reactions
Section 5.2:
'Elderly' replaced by 'older'
Updated on 13-Nov-2013 and displayed until 15-Oct-2014
Reasons for adding or updating:
- New individual SPC (was previously included in joint SPC)
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Combined SmPCGrunenthal Ltd
Units 1 and 2 Stokenchurch Business Park, Ibstone Road, Stokenchurch, Buckinghamshire, HP14 3FE, UK
+44 (0)870 351 8960
+44 (0)1494 486298
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue